SEATTLE — In this Healio Video Perspective from the ARVO meeting, Ashkan M. Abbey, MD, discusses efficacy and safety data for pegcetacoplan for geographic atrophy treatment at 36 months.
The GALE study is an extension of the phase 3 DERBY and OAKS studies, with 92% of patients carrying over to GALE. All patients in the extension study received pegcetacoplan, with a projected sham arm used as a comparator.
“We do see that there is increasing efficacy over the 36 months, with as few as six injections per year with pegcetacoplan,” (Read more...)